Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lumacaftor + ivacaftor in cystic fibrosis with homozygous F508del mutation
2012-003989-40Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing lumacaftor + ivacaftor with placebo (2 arms). Primary endpoint: Absolute change in percent predicted forced expiratory volume in 1 second (FEV1) from baseline at Week 24. Started Mar 2013; status: completed.
02
Drugs
lumacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2012-003989-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003989-40.